Publications by authors named "Y Terauchi"
Article Synopsis
- - Hydrophobins are specialized proteins that help fungal mycelium manage its interaction with air and surrounding mediums, with specific genes identified in the fungus Pleurotus ostreatus, particularly those encoding Vmh2, Vmh3, and Hydph16, which play key roles in its growth.
- - The study found that deleting the gene for Hydph16 resulted in a significant reduction in aerial mycelium density and a 40% decrease in cell wall thickness compared to control strains, while leaving major cell wall polysaccharide components intact.
- - Unlike Vmh2 and Vmh3, the absence of Hydph16 did not affect mycelial hydrophobicity, indicating that different hydrophobins
Aims/introduction: We previously showed that glucokinase haploinsufficiency improves the glucose tolerance of db/db mice by preserving pancreatic β-cell mass and function. In the present study, we aimed to determine the effects of glucokinase haploinsufficiency on the β-cell mass and function of long-term high-fat, high-sucrose (HFHS) diet-fed mice.
Materials And Methods: Four-week-old male glucokinase haploinsufficient (Gck) mice and 4-week-old male wild-type (Gck) mice (controls) were each divided into two groups: an HFHS diet-fed group and a normal chow-fed group, and the four groups were followed until 16, 40 or 60 weeks-of-age.
Aims/introduction: PIONEER REAL Japan was a non-interventional prospective study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice.
Materials And Methods: Adults naïve to injectable glucose-lowering therapies initiated oral semaglutide in routine clinical practice and were followed for 34-44 weeks. The primary endpoint was change in glycated hemoglobin (HbA) from baseline to end of study; the co-primary endpoint was number of adverse events (AEs).
Aims/introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors effectively and safely reduce fasting and postprandial hyperglycemia while promoting weight loss. However, their unique mechanism of action contributes to concerns regarding their safety. We therefore carried out a large-scale, non-commercial, investigator-initiated study on the safety and effectiveness of the SGLT2 inhibitor tofogliflozin.
View Article and Find Full Text PDFAims: This randomized, open-label, parallel-group, controlled trial compared the effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes.
Materials And Methods: For 24 weeks, participants received dulaglutide (0.75 mg/week) or trelagliptin (100 mg/week), after which beta-cell function was evaluated using a glucagon stimulation test-based disposition index.